Tenapanor Linked to Earlier, Sustained Symptom Relief in IBS-C

Patients with irritable bowel syndrome with constipation (IBS-C) treated with tenapanor experienced earlier improvement in bowel function and abdominal symptoms than those receiving placebo, according to a post hoc analysis of pooled randomized clinical trial data published in Therapeutic Advances in Gastroenterology.

Key Clinical Summary

• A post hoc pooled analysis of three randomized, placebo-controlled trials (n=1,372) found that tenapanor 50 mg twice daily shortened the time to first response for complete spontaneous bowel movements (CSBMs) and abdominal symptoms in IBS-C.

• Median time to first CSBM response was 2 weeks with tenapanor versus 4 weeks with placebo; median time to abdominal pain, discomfort, bloating, and composite abdominal symptom (AS3) response was 4–5 weeks versus 6–8 weeks, respectively.

• Higher weekly response rates were observed with tenapanor throughout the 12-week treatment period, supporting earlier and sustained symptom improvement compared with placebo.

Patients with IBS-C often seek therapies that provide rapid relief from both constipation and abdominal symptoms, which can substantially impair quality of life. A post hoc analysis published in Therapeutic Advances in Gastroenterology evaluated the onset and durability of symptom improvement with tenapanor using pooled data from three randomized, placebo-controlled clinical trials.

Study Findings 

The analysis pooled data from the phase IIb, T3MPO-1, and T3MPO-2 studies evaluating tenapanor 50 mg twice daily in adults with IBS-C. A total of 1,372 patients were included, with 684 receiving tenapanor and 688 receiving placebo.

Investigators assessed the time to first response for complete spontaneous bowel movement (CSBM) frequency, abdominal pain, abdominal discomfort, bloating, and a composite 3-item abdominal symptom score (AS3), which averaged weekly scores for pain, discomfort, and bloating. Cumulative response rates were estimated using the Kaplan-Meier method, while Cox proportional hazards modeling evaluated the influence of baseline and demographic characteristics on treatment response.

Patients treated with tenapanor achieved a median time to first CSBM response of 2 weeks, compared with 4 weeks among placebo recipients. Median time to first response for abdominal pain, discomfort, bloating, and the AS3 composite score ranged from 4 to 5 weeks with tenapanor, versus 6 to 8 weeks with placebo.

By week 12, 67.8% to 76.7% of patients receiving tenapanor had achieved a first response in CSBM frequency or abdominal symptoms, compared with 59.1% to 69.4% of those receiving placebo. Weekly response rates remained consistently higher with tenapanor than placebo across all evaluated endpoints throughout the 12-week treatment period.

Clinical Implications

The findings suggest that tenapanor may provide clinically meaningful symptom improvement earlier than placebo while maintaining higher response rates throughout treatment. For patients with IBS-C, earlier relief of constipation and abdominal symptoms such as pain, discomfort, and bloating may improve treatment satisfaction and quality of life.

Because symptom improvement often influences treatment adherence and patient expectations, understanding the expected time to response may help clinicians counsel patients beginning therapy with tenapanor. The analysis also indicates that benefits extend beyond bowel movement frequency to multiple abdominal symptoms, reflecting the multidimensional symptom burden experienced by patients with IBS-C.

As a post hoc analysis, however, these findings should be interpreted within the context of the original randomized trials. The analysis was designed to characterize the timing of response rather than establish new efficacy outcomes.

Expert Commentary

"This novel post hoc analysis demonstrates that, compared with placebo, tenapanor reduces the time to first response in CSBM frequency and abdominal symptoms and consistently increases the weekly response rate during 12 weeks of treatment," the investigators concluded.

The study was conducted by Brian E. Lacy, MD; Andrea S. Shin, MD; David J. Cangemi, MD; Yang Yang; Suling Zhao; and David P. Rosenbaum. The abstract did not provide institutional affiliations or additional expert commentary beyond the authors' conclusion.

The authors noted that earlier and sustained symptom relief may be particularly important for patients with IBS-C, in whom constipation and abdominal symptoms significantly affect daily functioning and quality of life.

This pooled post hoc analysis suggests that tenapanor provides earlier onset of improvement in bowel and abdominal symptoms than placebo and maintains higher weekly response rates over 12 weeks. Prospective studies designed to evaluate time-to-response endpoints may further clarify the clinical significance of these findings.

Reference

Lacy BE, Shin AS, Cangemi DJ, Yang Y, Zhao S, Rosenbaum DP. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis. Ther Adv Gastroenterol. 2026;19:17562848251414831. doi:10.1177/17562848251414831.